Trial · NCT03158532

Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin

NCT03158532, Phase 3, Completed, Instituto de Cardiologia de Santa Catarina; results first posted 2024-12-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin. Trials, record NCT03158532. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03158532

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin
NCT number: NCT03158532
Status: Completed
Phases: Phase 3
Enrollment: 2,040 participants, actual
Lead sponsor: Instituto de Cardiologia de Santa Catarina
Conditions: Injury of Radial Artery
Interventions: Nitroglycerin I, Placebo I, Nitroglycerin II, Placebo II
First posted: 2017-05-18
Last updated: 2024-12-09
Results first posted: 2024-12-09

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Radial Artery Occlusion	2 to 24 hours after procedure	Incidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound
Secondary	Late Radial Artery Occlusion	30 days after procedure	Incidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound
Secondary	Pain Assessment	up to 24 hours after procedure	Pain felt by the patient in the forearm, assessed using numeric pain rating scale ranging from 0 to 10, 0 best (no pain) 10 worst (unbearable pain)
Secondary	Spasm (Operator Evaluation)	During the realization of the procedure	Catheter friction, as experienced by the operator (subjective measure), during the realization of the procedure
Secondary	Procedure Duration	Duration of the procedure	Total duration of the procedure in seconds, from puncture to haemostatic dressing.
Secondary	Radiation Exposure	During the procedure	Total radiation used in the procedure

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Radial Artery Occlusion	2 to 24 hours after procedure	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Late Radial Artery Occlusion	30 days after procedure	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Pain Assessment	up to 24 hours after procedure	score on a scale	MEAN
SECONDARY	Spasm (Operator Evaluation)	During the realization of the procedure	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Procedure Duration	Duration of the procedure	seconds	MEAN
SECONDARY	Radiation Exposure	During the procedure	mGy	MEAN

Source ClinicalTrials.gov

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Radial Artery Occlusion	Placebo I/Placebo II	13		Participants
Radial Artery Occlusion	Nitroglycerin I/Placebo II	13		Participants
Radial Artery Occlusion	Placebo I /Nitroglycerin II	10		Participants
Radial Artery Occlusion	Nitroglycerin I /Nitroglycerin II	13		Participants
Late Radial Artery Occlusion	Placebo I/Placebo II	9		Participants
Late Radial Artery Occlusion	Nitroglycerin I/Placebo II	9		Participants
Late Radial Artery Occlusion	Placebo I /Nitroglycerin II	7		Participants
Late Radial Artery Occlusion	Nitroglycerin I /Nitroglycerin II	9		Participants
Pain Assessment	Placebo I/Placebo II	2.7	Standard Deviation .42	score on a scale
Pain Assessment	Nitroglycerin I/Placebo II	2.4	Standard Deviation .37	score on a scale

1 to 10 of 24Source ClinicalTrials.gov

See all 24 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo I/Placebo II	510
Overall Study	STARTED	Nitroglycerin I/Placebo II	510
Overall Study	STARTED	Placebo I /Nitroglycerin II	510
Overall Study	STARTED	Nitroglycerin I /Nitroglycerin II	510
Overall Study	COMPLETED	Placebo I/Placebo II	510
Overall Study	COMPLETED	Nitroglycerin I/Placebo II	510
Overall Study	COMPLETED	Placebo I /Nitroglycerin II	510
Overall Study	COMPLETED	Nitroglycerin I /Nitroglycerin II	510
Overall Study	NOT COMPLETED	Placebo I/Placebo II	0
Overall Study	NOT COMPLETED	Nitroglycerin I/Placebo II	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events4

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hypotension	Cardiac disorders	Placebo I/Placebo II	6	510	6
other	Hypotension	Cardiac disorders	Nitroglycerin I/Placebo II	12	510	12
other	Hypotension	Cardiac disorders	Placebo I /Nitroglycerin II	6	510	6
other	Hypotension	Cardiac disorders	Nitroglycerin I /Nitroglycerin II	13	510	13

Source ClinicalTrials.gov

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo I/Placebo II	0	510
Total, all-cause mortality	Nitroglycerin I/Placebo II	0	510
Total, all-cause mortality	Placebo I /Nitroglycerin II	0	510
Total, all-cause mortality	Nitroglycerin I /Nitroglycerin II	0	510
Total, other adverse events	Placebo I/Placebo II	6	510
Total, other adverse events	Nitroglycerin I/Placebo II	12	510
Total, other adverse events	Placebo I /Nitroglycerin II	6	510
Total, other adverse events	Nitroglycerin I /Nitroglycerin II	13	510
Total, serious adverse events	Placebo I/Placebo II	0	510
Total, serious adverse events	Nitroglycerin I/Placebo II	0	510

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03158532

GET https://conductscience.org/api/trials/v1/NCT03158532/results?page=2

API reference For AI assistants